Future growth expectations in earnings/operating earnings/profits/EPS?

Sudarshan Chemical Industries is on track to scale up revenue from recently commissioned capex over a conservative 4-year period, extending earlier 3-year guidance. The company expects EBITDA margins to improve structurally over 3-5 years, potentially exceeding pre-COVID levels of 15%, driven by an expanded specialty product portfolio. Current EBITDA margin improvements (12.8% in Q2 FY24 vs. 8.2% last year) are supported by volume growth, improved product mix, and softer raw material costs. Revenue growth is volume-driven despite a softening price regime; new product sales are ramping up

Current/ Expected Orderbook/ Pending Orders?

RIECO Industries, a subsidiary of Sudarshan Chemical Industries, has seen a significant increase in order book and revenues. Current year revenue for RIECO stands at INR 151 crores compared to INR 80 crores last year, indicating a strong upcycle in the capital goods industry. The company expects RIECO to continue this positive trend and improve further from INR 233 crores of revenue in the previous year. No specific details on total current or expected order book across the entire Sudarshan Chemical Industries business are provided. Management highlights ongoing good traction from the recently

Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned fundraising through debt or equity in the transcript provided. The company has focused on reducing net debt significantly, from INR 926 crores in Q2 FY'23 to INR 445 crores in Q2 FY'24, indicating a deleveraging approach rather than new borrowing. Management discussed internal capex and capacity ramp-up funded through existing resources, without reference to external fundraising. The Board is reviewing the status of RIECO Industries for possible divestment, which might be a source of funds, but no concrete fundraising plan is disclosed. Ov

Any current/future capex/capital investment/strategic investment?

Sudarshan Chemical Industries recently commissioned new capex with expanded product offerings, currently at lower utilization but on target for ramp-up (Page 11). The ramp-up and revenue scale-up from new capex are expected over a conservative 4-year period (Page 14). The new capex is largely focused on specialty pigments to increase specialty revenue share (Page 13). No mention of any new product development capex; the company states product development projects are complete (Page 8). The company is pursuing cost improvement and value chain integration projects (Page 7). Board is reviewing th

Future growth expectations in sales/revenue/volumes?

The company expects top-line growth to reach INR 3,000 to 3,300 crores over the next 3 to 4 years, with guidance revised to a slightly longer 4-year period considering current global conditions. Revenue growth is expected to be largely volume-driven, with softening raw material prices aiding margins. New capex and expanded product portfolio are on track, with meaningful ramp-up expected over the next 1-4 years. Growth is anticipated primarily from coatings, plastics, and cosmetics applications, with coatings expected to see larger growth. Export markets, including the U.S. and Europe, are targ

Sudarshan Chem.Q2 FY24Chemicals & Petrochemicals

Sudarshan Chem. Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,081P/E: 84.7Market Cap: ₹8.6K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

The company expects top-line growth to reach INR 3,000 to 3,300 crores over the next 3 to 4 years, with guidance revised to a slightly longer 4-year period considering current global conditions.
Revenue growth is expected to be largely volume-driven, with softening raw material prices aiding margins.
New capex and expanded product portfolio are on track, with meaningful ramp-up expected over the next 1-4 years.
Growth is anticipated primarily from coatings, plastics, and cosmetics applications, with coatings expected to see larger growth.
Export markets, including the U.S. and Europe, are targeted for increased penetration, including through improved distribution models.
Volume growth has been strong despite overall market softness, aided by market share gains in new geographies and product launches.
EBITDA margins are expected to improve beyond pre-COVID levels due to the specialty product mix and higher capacity utilization.

Margin guidance

Category 1

Sudarshan Chemical Industries is on track to scale up revenue from recently commissioned capex over a conservative 4-year period, extending earlier 3-year guidance.
The company expects EBITDA margins to improve structurally over 3-5 years, potentially exceeding pre-COVID levels of 15%, driven by an expanded specialty product portfolio.
Current EBITDA margin improvements (12.8% in Q2 FY24 vs. 8.2% last year) are supported by volume growth, improved product mix, and softer raw material costs.
Revenue growth is volume-driven despite a softening price regime; new product sales are ramping up progressively and expected to contribute significantly in coming years.
Export volumes have grown steadily (5% increase in H1 FY24 YoY) despite global destocking and market pressures.
The company anticipates long-term margin momentum due to higher utilization and new product scaling, targeting margins above previous peaks.
Profit after tax showed improvement from INR5 crores to INR18 crores YoY in Q2 FY24, indicating positive future earnings trajectory.

See what Sudarshan Chem. management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of any current or planned fundraising through debt or equity in the transcript provided.
The company has focused on reducing net debt significantly, from INR 926 crores in Q2 FY'23 to INR 445 crores in Q2 FY'24, indicating a deleveraging approach rather than new borrowing.
Management discussed internal capex and capacity ramp-up funded through existing resources, without reference to external fundraising.
The Board is reviewing the status of RIECO Industries for possible divestment, which might be a source of funds, but no concrete fundraising plan is disclosed.
Overall, no announcements or plans for fresh debt or equity fundraising were communicated in this call.

Order book

RIECO Industries, a subsidiary of Sudarshan Chemical Industries, has seen a significant increase in order book and revenues.
Current year revenue for RIECO stands at INR 151 crores compared to INR 80 crores last year, indicating a strong upcycle in the capital goods industry.
The company expects RIECO to continue this positive trend and improve further from INR 233 crores of revenue in the previous year.
No specific details on total current or expected order book across the entire Sudarshan Chemical Industries business are provided.
Management highlights ongoing good traction from the recently commissioned capex and product portfolio, with a ramp-up expected over a 4-year period.
Engagement with European distribution tie-ups is active, aiming to expand mid-size and smaller customer approvals and grow sales in the medium term.

See what Sudarshan Chem. management said on order book — free account, 30 seconds.

Capex plans

Yes

Sudarshan Chemical Industries recently commissioned new capex with expanded product offerings, currently at lower utilization but on target for ramp-up (Page 11).
The ramp-up and revenue scale-up from new capex are expected over a conservative 4-year period (Page 14).
The new capex is largely focused on specialty pigments to increase specialty revenue share (Page 13).
No mention of any new product development capex; the company states product development projects are complete (Page 8).
The company is pursuing cost improvement and value chain integration projects (Page 7).
Board is reviewing the strategic decision on divesting subsidiary RIECO Industries but no final decision yet (Page 9).
Investment in European distribution set-up expanded with a pan-European distributor to enhance market reach (Pages 9 & 15).

Track Sudarshan Chem. — get its next earnings analysis in your feed

How does Sudarshan Chem. rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisSudarshan Chem.

Rev 3Mar 1

See where Sudarshan Chem. sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Sudarshan Chem. rank in Chemicals & Petrochemicals?

Compare Sudarshan Chem. against every Chemicals & Petrochemicals company (Q2 FY24) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Sudarshan Chem.'s management said in earlier quarters

Others in Chemicals & Petrochemicals this season

POCL Enterprises Ltd (Q1 FY27)
466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto
Deepak Nitrite Ltd (Q2 FY27)
Q2 FY27 total revenue: ₹3,091 crore, up 61% YoY (Page 1, 4, 5, 6, 10, 11) . Key investor presentation takeaways from Deepak Nitrite Ltd's Q2 FY27 investor prese
Privi Speciality Chemicals Ltd (Q2 FY27)
19,239.47 lakhs (approximately 33.9% growth). Key results statement takeaways from Privi Speciality Chemicals Ltd's Q2 FY27 results statement — and how it ranks
NOCIL Ltd (Q2 FY27)
427 crores . Key investor presentation takeaways from NOCIL Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.

Compare:vs Solar Industries vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →